{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:41:07Z","timestamp":1782866467546,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ajo.2011.05.040","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T11:04:32Z","timestamp":1313579072000},"page":"329-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Emerging Evidence Concerning Systemic Safety of Anti-VEGF Agents \u2013 Should Ophthalmologists Be Concerned?"],"prefix":"10.1016","volume":"152","author":[{"given":"Laurence S.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9583","key":"10.1016\/j.ajo.2011.05.040_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(07)61104-0","article-title":"Clinical update: new treatments for age-related macular degeneration","volume":"370","author":"Wong","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2011.05.040_bib2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","article-title":"A review of clinical trials of anti-VEGF agents for diabetic retinopathy","volume":"248","author":"Nicholson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"22","key":"10.1016\/j.ajo.2011.05.040_bib3","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1003934","article-title":"Clinical practice","volume":"363","author":"Wong","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajo.2011.05.040_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2011.05.040_bib5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"10.1016\/j.ajo.2011.05.040_bib6","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajo.2011.05.040_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2011.05.040_bib8","unstructured":"Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). Forthcoming."},{"issue":"1","key":"10.1016\/j.ajo.2011.05.040_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/14740330903418422","article-title":"Clinical safety of ranibizumab in age-related macular degeneration","volume":"9","author":"Schmidt-Erfurth","year":"2010","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.ajo.2011.05.040_bib10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/eye.2009.84","article-title":"Should avastin be used to treat age-related macular degeneration in the NHS?\u2014No","volume":"23","author":"Chong","year":"2009","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.ajo.2011.05.040_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/bjo.2009.178574","article-title":"Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review","volume":"95","author":"Schmucker","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2011.05.040_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"issue":"1-2","key":"10.1016\/j.ajo.2011.05.040_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.ajo.2011.05.040_bib14","first-page":"161","article-title":"Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy","volume":"31","author":"Qian","year":"2011","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.ajo.2011.05.040_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","article-title":"Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab","volume":"94","author":"Matsuyama","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2011.05.040_bib16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2011.05.040_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1600-0420.2007.00926.x","article-title":"Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections","volume":"85","author":"Mennel","year":"2007","journal-title":"Acta Ophthalmol Scand"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411004673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411004673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:03:58Z","timestamp":1757595838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939411004673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0002939411004673"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2011.05.040","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Evidence Concerning Systemic Safety of Anti-VEGF Agents \u2013 Should Ophthalmologists Be Concerned?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2011.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}